 |
 |
 |
|
QUARTZ-I: OMBITASVIR/PARITAPREVIR/R, DASABUVIR, AND SOFOSBUVIR TREATMENT OF PATIENTS WITH HCV GENOTYPE 1-INFECTION WHO FAILED A PRIOR COURSE OF DAA THERAPY
|
|
|
Reported by Jules Levin
Digestive Disease Week • San Diego, California • 23 May 2016
Fred Poordad1, Michael Bennett2, Thomas E Sepe3, Eric Cohen4,
Robert W Reindollar5, Gregory Everson6, Raymond W Phillips7, Asma Siddique8, J Greg Sullivan9, Terry D Box10, Bo Fu4, Tami Pilot-Matias4, Manal Abunimeh4, Daniel E Cohen4, Ziad Younes11
1The Texas Liver Institute/University of Texas Health Science Center, San Antonio, Texas, United States; 2Medical Associates Research Group, San Diego, California, United States; 3Liver Center, University Gastroenterology, Providence, Rhode Island, United States; 4AbbVie Inc., North Chicago, Illinois, United States; 5Piedmont Healthcare/Carolinas Center for Liver Disease, Statesville, North Carolina, United States; 6University of Colorado Denver School of Medicine, Aurora, Colorado, United States; 7Gastroenterology Group of Naples PA, Naples, Florida, United States; 8Virginia Mason Hospital and Medical Center, Seattle, Washington, United States; 9Parkway Medical Center, Birmingham, Alabama, United States; 10Clinical Research Centers of America, Murray, Utah, United States; 11GastroOne, Germantown, Tennessee, United States




NS3 inhibitor class variants included in the analysis: GT1a: V36A/G/I/L/M, F43L, T54A/S, V55A/I, Y56H, Q80K/R, V107I, S122G/R, I132V, R155(all), A156(all), V158I, D168(all), and I170F/T/V; GT1b: V36A/G/I/L/M, T54A/C/G/S, V55A, Y56H/L, Q80K/R, V107I, S122A/D/G/I/N/T, R155(all), A156(all), V158I, D168(all), V170A/T, and M175L.
NS5A inhibitor class variants included in the analysis: GT1a: M28(all), Q30(all), L31(all), P32L, H58D/R, and Y93(all); GT1b: L28(all), P29S/del, R30G/H/P/Q, L31(all), P32L/del, P58A/S, Q62D, A92E/K, and Y93(all).
NS5B non-nucleoside palm site inhibitor class variants included in the analysis: GT1a: L314H, C316Y, M414I/T/V, E446K/Q, Y448C/H, C451R, A553T, G554S, Y555H, S556G/R, G557R, G558R, D559G/N, and Y561H/N; GT1b: C316H/N/W/Y, S368T, N411S, M414I/T/V, C445F/Y, Y448C/H, A553V, S556G, and D559G.



|
|
|
 |
 |
|
|